红光闪烁治疗仪联合红色视力表远距离视功能训练对儿童近视性弱视的影响

目的：探讨红光闪烁治疗仪联合红色视力表远距离视功能训练对儿童近视性弱视的影响。

方法：将我院收治的112例近视性弱视患儿分组,对照组予短小遮盖+近距离功能性视力训练,观察组在此基础上予红光闪烁治疗仪联合红色视力表远距离视功能训练。比较两组患儿临床疗效和治疗前后屈光动态变化、BCVA、弱视复发率。

结果：观察组的临床总有效率高于对照组(P<0.05)。治疗后,观察组近视性屈光度与治疗前对比无差异(P>0.05),而对照组随时间延长逐渐升高(P<0.05); 观察组治疗1a后的近视性屈光度、年均屈光度变化值和弱视复发率低于对照组(P<0.05)。两组患儿治疗后BCVA优于治疗前,治疗1a时优于治疗6mo(P<0.05)。

结论：红光闪烁治疗仪联合红色视力表远距离视功能训练治疗儿童近视性弱视可有效降低年平均屈光度变化值,矫正最佳视力,降低弱视复发率。     

Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-negative Cohort: Long-term Management and Complications

Abstract

Purpose: To examine the clinical outcomes achieved by using intravitreal ganciclovir injections combined with systemic anti-viral therapy in treating cytomegalovirus (CMV) retinitis in patients without human immunodeficiency virus (HIV) infection.

Methods: Twenty-three eyes of 15 HIV-negative patients diagnosed with CMV retinitis were included in this retrospective study.

Results: The median follow-up was 68 weeks (range, 12–156), and median number of injections was 10 (range, 2–22). The retinal lesions stopped progressing within 1–2 weeks following treatment. All of the eyes showed either unchanged or ≥2?line improvements of BCVA at last visit. There was no development of CMV retinitis in a fellow eye, or recurrence in a studied eye. Systemic complications such as neutropenia were not detected.

Conclusions: Intravitreal ganciclovir injections combined with systemic anti-viral treatment is a good therapeutic option for treating CMV retinitis without HIV infection. Such treatment provided favorable visual outcomes, with minimal ocular and systemic complications.     

静脉注射免疫球蛋白治疗糖皮质激素耐药的NMO-ON复发患者的疗效

目的:探讨静脉注射免疫球蛋白(IVIG)治疗糖皮质激素耐药的视神经脊髓炎相关性视神经炎(NMO-ON)复发患者的临床疗效。方法:前瞻性研究。选择2016-01/2018-01我院眼科住院部收治的79例对糖皮质激素耐药的NMO-ON复发患者,根据治疗方式将其分为两组,IVIG组42例57眼采用IVIG治疗,血浆置换(PE)组37例43眼采用PE治疗。比较两组患者疗效、不良反应和复发率,以及治疗前后裸眼视力、水通道蛋白4抗体(AQP4-IgG)、髓鞘少突胶质细胞糖蛋白抗体(MOG-IgG)抗体变化。结果:IVIG组和PE组治疗有效率均为91%(P>0.05);两组患者治疗后裸眼视力分布情况较治疗前明显改善(P<0.01),AQP4-IgG(+)、MOG-IgG(+)比例均较治疗前明显下降(P<0.001),而以上指标两组间比较无差异(P>0.05)。两组患者中位随访40(29~50)mo,截止末次随访IVIG组、PE组复发率分别为10%、9%(P>0.05)。IVIG组治疗过程中不良反应发生率低于PE组(P<0.05)。结论:PE、IVIG均能改善糖皮质激素耐药的NMO-ON复发患者视力和症状,清除致病抗体,降低复发,但IVIG安全性相对较高。     

Effectiveness of Treatments for Ocular Toxoplasmosis

ABSTRACT

Purpose: To evaluate the effectiveness of treatments for ocular toxoplasmosis (OT).

Methods: A review of charts was conducted from patients who experienced an active episode of OT treated at the Federal University of São Paulo and associated sites. OT charts were reviewed to determine treatment effectiveness based on clinical judgment, taking clinical course and outcome into consideration in addition to change in best-corrected visual acuity. Treatment emergent adverse events (TEAEs) were used to assess safety.

Results: Overall, 451/1200 patient charts met the inclusion criteria. The most commonly prescribed treatment was trimethoprim + sulfamethoxazole (52.3%) followed by pyrimethamine + sulfadiazine (28%). Treatment was successful in 96.9% of patients. Irrespective of the treatment, active lesions were resolved in 63.9% of patients within 6 weeks. Vision improved in 56.3% of patients. The incidence of TEAEs was low (10%).

Conclusions: All treatments were effective for active episodes of OT, with few side effects.     

Serpiginous-Like Choroiditis (SLC) – Morphology and Treatment Outcomes

ABSTRACT

Purpose: To study morphology and treatment outcomes in serpiginous-like choroiditis (SLC).

Methods: A retrospective chart review of SLC cases with ≥1-year follow-up. SLC lesions with elongated borders, thin body named dendritic (D-SLC), large lesions still with elongated borders named advanced dendritic (AD-SLC), and lesions with rounded borders, thick body called placoid (P-SLC). History, investigations, treatment response, and relapses were studied.

Results: Thirty-three eyes [D-SLC (n = 14), AD-SLC (n = 13), P-SLC (n = 6)] of 24 patients were studied. Resolution on Fundus autofluorescence achieved at 8.6 months (Range: 4–12 months). 0/16 eyes treated with anti-tubercular therapy (ATT) and 4/11 eyes treated without ATT had at least one recurrence in (D-SLC + AD-SLC) group (p = .019). Mean best corrected visual acuity at final follow-up was 20/20, 20/25, and 20/60 in D-SLC, AD-SLC, and in P-SLC, respectively.

Conclusion: P-SLC has poor visual prognosis compared to AD-SLC and D-SLC. ATT may prevent recurrences in D-SLC and AD-SLC.     

视知觉感知训练联合全营养餐序贯疗法治疗学龄前儿童近视性弱视的效果评价

目的:观察视知觉感知训练联合全营养餐序贯疗法治疗近视性弱视患儿的治疗效果.方法:将本院收治的73例135眼近视性弱视患儿按照随机数字表法分为对照组(36例67眼)和治疗组(37例68眼).对照组采用传统的带镜遮盖联合精细目力和光栅训练进行治疗;治疗组采用视知觉感知训练联合全营养餐序贯疗法进行治疗.比较两组患儿治疗前和治疗3、6mo,1a的视力、屈光度及年均屈光度变化值;比较两组患儿治疗1a的疗效,并对两组患儿治疗期间的不良反应发生情况进行记录;比较两组患儿中基本治愈的患儿随访1a期间弱视的复发率.结果:治疗3mo,两组患儿的BCVA比较,差异无统计学意义(P>0.05);治疗6mo,1a,治疗组的BCVA均显著优于对照组,差异均有统计学意义(P<0.05).两组治疗3、6mo,1a后的屈光度均无显著差异(P>0.05),但治疗组的年均屈光度变化值显著低于对照组(P<0.05).治疗组的基本治愈率和总有效率均显著高于对照组(P<0.05).两组患儿在治疗期间均无严重不良反应的发生.随访1a,治疗组基本治愈患儿的弱视复发率显著低于对照组(P<0.05).结论:视知觉感知训练联合全营养餐序贯疗法治疗近视性弱视能显著改善视力,降低年均屈光度变化值,提升患儿的治疗效果,降低弱视复发率.     

玻璃体切割术联合激光治疗PDR的疗效观察

目的：探讨玻璃体切割术与激光治疗在增生性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)中的联合应用价值。

方法：选取我院2009-03/2010-03收治的PDR患者89例116眼,随机将患者分为对照组(47例62眼)和研究组(42例54眼)。对照组患者采用玻璃体切割术治疗,研究组患者在对照组患者治疗基础上,联合眼内激光进行治疗。比较分析患者治疗前后最佳矫正视力变化情况, FFA检查结果以及治疗后并发症发生情况。

结果：与治疗前相比,对照组和研究组治疗后最佳矫正视力<0.1的患者比率明显减少,分别为40%和28%,最佳矫正视力0.5～1.0的比率明显提高,分别达到24%和41%,差别均具有统计学意义(P<0.05)。与对照组患者治疗后相比,研究组患者治疗后最佳矫正视力0.5～1.0的比率明显提高,黄斑水肿消退或部分消退比率明显提高,而黄斑水肿加重、视网膜渗漏以及玻璃体再次出血比率明显降低,差别均具有统计学意义(P<0.05)。

结论：玻璃体切割术联合激光是治疗PDR的有效方案,对患者术后视力的提高和并发症的降低具有积极的促进作用。     

高压氧联合卵磷脂络合碘治疗中心性浆液性脉络膜视网膜病变

目的:探讨高压氧联合卵磷脂络合碘治疗中心性浆液性脉络膜视网膜病变的疗效及安全性。方法:将2008-07/2012-07入住我院的100例118眼中心性浆液性脉络膜视网膜病变患者按照抽签法随机地均分为对照组与观察组。对照组仅给予高压氧进行治疗,观察组在此基础上联合卵磷脂络合碘进行治疗。比较两组临床治疗效果、治疗后不同时间临床愈合情况、治疗前后视力、复发率以及不良反应发生情况。结果:(1)对照组总眼数60眼,治疗有效眼数43眼,总有效率为71.7%;观察组总眼数58眼,治疗有效眼数51眼,总有效率为87.9%,两组临床疗效相比具有统计学差异(P<0.05);(2)两组治疗后2,4wk及3mo恢复正常眼数相比,差异均具有统计学意义(P<0.05,P<0.01);(3)两组治疗前后视力差异均具有统计学意义(P<0.05,P<0.01),且观察组治疗后视力明显优于对照组治疗后视力(P<0.05);(4)经1a的随访,对照组复发眼数为6眼,复发率为10.0%;观察组复发率为0眼,两组差异具有极显著的统计学意义(P<0.01);(5)两组治疗过程中不良反应发生率无统计学差异(P>0.05)。结论:高压氧联合卵磷脂络合碘治疗中心性浆液性脉络膜视网膜病变的疗效显著,安全性高,值得在临床治疗中心性浆液性脉络膜视网膜病变中加以推广并应用。     

巩膜扣带术联合23G玻璃体切割术治疗眼球内异物伴视网膜脱离

目的：探讨巩膜扣带术结合23G玻璃体切割术对眼球内异物伴视网膜脱离的治疗效果。

方法：将2014-01/2018-01收治的72例眼球内异物伴视网膜脱离患者以随机数字表法分为对照组36例和观察组36例,对照组行23G玻璃体切割术,观察组在对照组基础上行巩膜扣带术,观察两组术前、硅油取出3mo后眼压及视力变化、复位成功、复发情况及术后并发症发生情况。

结果：术前两组眼压及BCVA均无差异(P>0.05),硅油取出后3mo,两组眼压及BCVA均较术前有明显改善(P<0.05),两组组间无差异(P>0.05); 观察组与对照组一次手术解剖复位成功率分别为97%、81%(P<0.05),观察组与对照组复发率分别为6%、25%(P<0.05); 观察组术后并发症发生率为22%,对照组31%(P>0.05)。

结论：巩膜扣带术联合23G玻璃体切割术治疗眼球内异物伴视网膜脱离,可显著改善患者眼压及视力,提高复位成功率,减少复发,且安全性较高。     

复方樟柳碱注射液治疗中心凹旁型中浆病

目的：观察复方樟柳碱注射液治疗中心凹旁型中心性浆液性脉络膜视网膜病变(CSC,简称中浆病)的临床疗效和安全性。

方法：将60例60眼确诊为中心凹旁型CSC患者随机分为治疗组32例32眼和对照组28例28眼,治疗组采用复方樟柳碱注射液2mL,予患眼侧颞浅动脉旁皮下注射,每日1次,对照组给予传统药物口服治疗,疗程均为2～4个疗程。以患者最佳矫正视力(BCVA)、自觉症状、视野、平均光敏感度及OCT结果为主要观察指标。

结果：治疗前两组各指标无显著性差异(P>0.05),治疗后1,3mo治疗组各项指标均比对照组显著好转(P<0.05),治疗后6mo两组之间均无显著性差异(P>0.05)。治疗组除个别患者有短暂口干、头晕及心慌外,未发现严重不良反应。

结论：复方樟柳碱注射液治疗中心凹旁型CSC患者的效果明显,可缩短病程,改善视功能,降低复发率。     

自体角膜缘干细胞移植联合丝裂霉素C在合并T2DM的翼状胬肉患者中的应用效果

目的：：探讨自体角膜缘干细胞移植联合低浓度丝裂霉素C对于合并2型糖尿病( T2 DM )的翼状胬肉患者中的应用效果和安全性。方法：将本院收治的80例96眼翼状胬肉患者分为高浓度组、低浓度组、对照组,3组患者均给予翼状胬肉切除联合自体角膜缘干细胞移植,高浓度组、低浓度组在干细胞移植前分别给予0.2,0.1mg/mL 丝裂霉素 C 棉片覆盖。比较3组患者的愈合和复发情况,以及治疗前后裸眼视力。结果：治疗前3组患者裸眼视力均无显著差异(P>0.05),3组患者治疗后裸眼视力均得到显著改善( P<0.05);高浓度组上皮愈合时间显著高于低浓度组和对照组(P<0.05),低浓度组和对照组上皮愈合时间无显著差异(P>0.05);低浓度组治愈率高于高浓度组,复发率低于高浓度组。结论：翼状胬肉切除联合自体角膜缘干细胞移植对于翼状胬肉疗效确切,联合丝裂霉素C能够有效降低复发率,但对于合并T2 DM患者应当降低丝裂霉素C浓度。     

激光治疗中浆的临床观察及视力同渗漏位置的相关性研究

目的：分析低能量视网膜激光光凝术治疗中心性浆液性脉络膜视网膜病变（ central serous chorioretinopathy, CSC ）的临床效果以及视力同渗漏位置的相关性。 方法：采用低能量激光治疗渗漏点在黄斑旁中心凹外的53例中浆患者行激光封闭为治疗组。常规药物治疗的33例为对照组。对比观察两组患者治疗前后自觉症状、眼底、眼底荧光血管造影（ fundus fluorescein angiography, FFA）的改变,眼底光学相干断层扫描（ optical coherence tomography,OCT）检查,视力提高程度,以及治愈率、复发率。对全部126例患者的视力同渗漏位置进行相关性分析。 结果：治愈率比较：治疗组术后4 wk治愈率为92.5%,对照组在用药后4 wk治愈率为30.3%。两组相比,有显著性差异（P〈0.01）,治疗组和对照组在治疗后2,4wk;3,6 mo均存在显著性差异（ P〈0.01）。对照组复发率为12.1%,治疗组复发率为11.3%。两组相比,无显著差异性（P〉0.05）。非参数相关分析法对视力与荧光渗漏点位置之间的关系进行比较,其相关系数 r=0.216, P =0.0001,两者存在着线性正相关关系。 结论：低能量激光对渗漏点在黄斑旁中心凹外的患者早期进行激光治疗,可以缩短病程,提高视力和临床治愈率,提高视觉质量,但不能降低复发率。视力与渗漏位置呈正相关性,对判断预后及治疗有临床指导作用。     

Infliximab-induced Demyelination Causes Visual Disturbance Mistaken for Recurrence of HLA-B27-related Uveitis

Purpose: To report a patient treated with infliximab for ankylosing spondylitis and HLA-B27 uveitis presenting with a scotoma in his left good eye due to infliximab-induced occipital demyelination mistaken for a uveitis recurrence.

Design: Case report.

Methods: Review of clinical features, visual field, and investigational procedures.

Results: Loss of visual function could not be explained by mere ophthalmic examination. Magnetic resonance imaging showed several demyelinating lesions, explaining the patient’s symptoms and signs. Infiliximab was discontinued and the scotoma disappeared.

Conclusion: This is the first report of infliximab-induced demyelination producing ocular symptoms and signs in a patient treated for uveitis.     

翼状胬肉切除联合自体角膜缘干细胞移植术后硬性角膜接触镜的干预效果

目的:探讨老年翼状胬肉切除与自体角膜缘干细胞移植术后硬性角膜接触镜的干预效果.方法:选取2015-03/2016-03经我院诊断为单侧翼胬肉老年患者90例90眼进行分组对比研究.观察组45例45眼采用自体角膜缘干细跑移植术后硬性角膜接触镜,对照组45例45眼行单纯自体角膜缘干细胞移植术.两组患者观察指标包括:角膜愈合时间和术后1、3、5、7d时两组患者疼痛程度(VAS评分)、胬肉复发几率.结果:观察组和对照组的角膜刺激症状评分存在统计学差异,观察组评分显著低于对照组患者(P<0.05).对照组患者角膜愈合时间高于观察组患者,差异具有统计学意义(P<0.05);VAS评分显示,术后1、2d时对照组患者高于观察组,两组比较差异具有统计学意义(P<0.05);两组患者胬肉愈合复发几率对比,差异无统计学意义(P>0.05).结论:自体角膜干细胞移植术后结合硬性角膜接触镜对老年翼状胬肉效果明显,患者愈合较快,还可减轻患者术后疼痛感,同时不会增加胬肉复发率.     

Ocular toxoplasmosis: clinical features and prognosis of 154 patients

PURPOSE: To ascertain the clinical features, visual outcome, and recurrence rates of ocular toxoplasmosis (OT) in a large series of patients. To determine the efficacy of various treatment strategies and identify the patients at risk of visual loss. DESIGN: Retrospective noncomparative observational case series. PARTICIPANTS: One hundred fifty-four consecutive patients with active lesions of OT (first attack and/or recurrence) were identified in a cohort of 1300 consecutive patients with uveitis. Mean follow-up was 5.8 years. INTERVENTION: A review of the medical records of 154 patients with active OT. MAIN OUTCOME MEASURES: Patients were subdivided according to clinical and laboratory criteria. Numerous variables were compared per patient and group, including age and gender distribution, onset and course of infection, clinical ocular features, laboratory data, therapeutic strategies and their outcomes, number of recurrences, complications, final visual acuity, and features associated with poor visual outcome. RESULTS: Primary retinal lesions were observed in 28% and a combination of active lesions and old retinochoroidal scars in 72% of the patients at first presentation to the ophthalmologist. Mean age at first presentation with an active OT lesion was 29.5 years. Patients with primary OT were older than those with a combination of active lesions and old scars (P < 0.001). Serologic characteristics of the acute phase of systemic infection were found in 11% of the patients. Ocular involvement in these patients was associated with advanced age at onset (P < 0.001) and was characterized by severe intraocular inflammation. Most (82%) of the patients with serologic characteristics of the acute phase of systemic infection had primary lesions (compared with 23% of OT in the chronic phase of systemic infection; P < 0.001). Extensive retinal lesions were more frequently observed during the acute phase of systemic infection (P = 0.02) and in patients with primary OT (P < 0.04). Recurrences, which developed in 79% of all patients followed for more than 5 years, were located predominantly in previously affected eyes (with old scars) in contrast to the sporadic cases of recurrence in the healthy contralateral eye (P < 0.0001). Standard short-term therapeutic modalities had no effect on visual outcome or future recurrence rates. Legal blindness in one or both eyes was confirmed for 24% of the patients. Blindness of both eyes was more frequent in patients with congenital OT (P < 0.001). Risk factors for visual loss included congenital infection, OT manifesting during the acute phase of systemic infection, central location and/or extensive retinal lesions, and the administration of corticosteroids without a shield of antiparasitic drugs. CONCLUSIONS: Legal blindness in at least one eye developed in 24% of the patients with OT. Recurrences, which developed in 79% of the patients with long-term follow-up, were located predominantly in eyes with toxoplasmic scars. Various short-term therapeutic modalities had no effect on visual outcomes or future recurrence rates, with the exception of a poor visual outcome for patients who received corticosteroids without a shield of antiparasitic drugs.     

血栓通联合羟苯磺酸钙治疗糖尿病视网膜病变导致的视野缺损

目的:探讨血栓通联合羟苯磺酸钙应用于糖尿病视网膜病变导致的视野缺损的临床疗效.方法:选取我院收治的糖尿病视网膜病变患者64例作为研究对象,将其随机均分为观察组和对照组,对照组采用血栓通进行治疗,观察组在上述治疗的基础上加用羟苯磺酸钙进行联合治疗.治疗5 mo后,比较两组糖尿病视网膜病变患者的临床疗效,治疗前后视野、荧光造影及眼底照相变化情况,观察患者的不良反应及复发情况.结果:两组患者的病情均明显好转,且观察组患者治疗有效率为97％,高于对照组的78％,差异比较有统计学意义(P＜0.05);观察组患者出血斑明显降低治疗前后比较有显著性差异,具有统计学意义(P＜0.05),观察组的视野灰度值、出血斑、血管瘤变化情况均明显优于对照组,具有统计学意义.观察组患者未出现不良反应,且复发率明显少于对照组,复发率比较有显著性差异(P＜0.05).结论:血栓通联合羟苯磺酸钙对糖尿病视网膜病变患者进行治疗,取得了比较满意的疗效,可以有效降低复发率,减少不良反应,显著改善临床症状,可在临床上推广应用.     

更昔洛韦眼用凝胶联合脾氨肽治疗上皮型单纯疱疹病毒性角膜炎

目的：观察更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型单纯疱疹病毒性角膜炎(HSK)的效果。

方法：选取2015-01/2016-06在我院眼科门诊确诊的70例70眼HSK患者,随机分为对照组和试验组。两组患者均采用更昔洛韦眼用凝胶治疗,试验组在此基础上口服脾氨肽冻干粉。两组患者连续用药30d。比较两组患者的临床治愈率、角膜溃疡愈合时间、疼痛减轻时间、畏光消失时间、视力改善情况及复发率等。

结果：治疗30d后,试验组患者临床治愈率(80%)显著高于对照组(51%),差异有统计学意义(P<0.05)。与对照组相比,试验组患者角膜溃疡愈合时间、疼痛缓解时间及畏光消失时间均缩短,差异均有统计学意义(P<0.05)。随访1a,试验组患者复发率为14%,对照组为67%,试验组复发率低于对照组,差异有统计学意义(P<0.05)。

结论：更昔洛韦眼用凝胶联合脾氨肽口服冻干粉治疗上皮型HSK疗效好,能显著提高视力及临床治愈率,缩短病程,降低复发率。     

复明片对视网膜脱离复位术后视神经功能恢复的疗效

目的：评价中药复明片对视网膜脱离复位术后患者视神经功能恢复的疗效。 方法：采用分组对照研究的方法,将我院2010-01/2013-01收治的视网膜脱离复位术患者60例,根据治疗方法随机分为复明片治疗组（观察组）30例和甲钴胺注射液治疗组（对照组）30例。随访6wk,记录并对比分析两组患者视力、眼压、眼底情况以及视网膜神经纤维层厚度（ RNFLT）。 结果：观察组视力、眼底有效率分别为90%,97%,对照组分别为77%,80%,两组比较差异有显著统计学意义（ P〈0.01）。两组患者在治疗后暗适应和明适应ERG a、b波振幅及治疗前后暗适应和明适应a、b波振幅的差值有显著性意义（P〈0.05）,而眼压无明显统计学差异（P〉0.05）。 结论：复明片能促进视网膜复位术后视网膜下液体的吸收,促进视神经恢复,改善视功能。     

角膜缘上皮移植与羊膜移植治疗原发性翼状胬肉的对比观察

目的：对比观察翼状胬肉切除联合角膜缘上皮移植术与羊膜移植术对原发性翼状胬肉复发率的影响。
　　方法：采用随机对照分组的方法将我院手术治疗的原发性翼状胬肉患者99例103眼随机分为A,B两组。 A组为角膜缘上皮移植术组( n=54眼),采用翼状胬肉切除联合角膜缘上皮移植术;B组为羊膜移植术组( n=49眼),采用翼状胬肉切除联合羊膜移植术。术后随访1a,以泪膜破裂时间( breaking-up time,BUT)、复发率等指标作为分析参考指标。
　　结果：术后1a,联合角膜缘上皮移植术组有4眼(7.4%)复发。联合羊膜移植术组有11眼(22.5%)复发。两组复发率比较,差异有统计学意义( P<0.05)。两组间BUT比较无统计学意义(P>0.05)。
　　结论：相比羊膜移植术,翼状胬肉切除联合角膜缘上皮移植术治疗原发性翼状胬肉,能更有效的降低术后复发率。     

羟苯磺酸钙对PDR患者全视网膜激光光凝术后玻璃体积血的影响

目的：探讨羟苯磺酸钙对增生期糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)患者全视网膜激光光凝术后玻璃体积血的影响。

方法：以2015-01/2017-07我院收治的PDR患者62例92眼(30例双眼,32例单眼)为研究对象,依据医师建议和患者自愿原则分为对照组(行全视网膜激光光凝术治疗,30例43眼,单眼17例,双眼13例)和研究组(全视网膜激光光凝术联合羟苯磺酸钙治疗,32例49眼,单眼15例,双眼17例)。观察治疗后两组患者视力恢复情况、血液流变学(血浆黏度、红细胞比容、红细胞变形指数)和术后玻璃体积血等并发症发生率。

结果：治疗前两组患者视力优良率、血浆黏度、红细胞比容、红细胞变形指数比较,差异无统计学意义(P>0.05); 治疗后研究组视力优良率明显高于对照组(P<0.05); 治疗后仅研究组血浆黏度和红细胞比容明显降低,红细胞变形指数明显升高,且治疗后研究组各项指标变化较对照组明显(P<0.05); 研究组术后玻璃体积血发生率和并发症总发生率明显低于对照组,差异有统计学意义(P<0.05)。

结论：羟苯磺酸钙应用于PDR患者全视网膜激光光凝术后,可有效提高患者视力恢复效果、降低玻璃体积血等并发症发生率,机制可能与其有效改善患者血流动力学有关。